Wedmont Private Capital Acquires 106,561 Shares of Organon & Co. $OGN

Key Points

• Wedmont Private Capital increased its holdings in Organon & Co. by 233.9% during the second quarter, now owning a total of 152,118 shares valued at approximately $1.5 million.
• Organon & Co. reported $1.00 earnings per share for the last quarter, exceeding analyst estimates, despite a 0.8% decline in year-over-year quarterly revenue.
• The company announced a quarterly dividend of $0.02 per share, reflecting an annualized payout of $0.08 and a yield of 0.7%.

Wedmont Private Capital raised its stake in shares of Organon & Co. (NYSE:OGN - Free Report) by 233.9% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 152,118 shares of the company's stock after acquiring an additional 106,561 shares during the period. Wedmont Private Capital owned about 0.06% of Organon & Co. worth $1,507,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Ransom Advisory Ltd bought a new position in Organon & Co. during the 1st quarter valued at $32,000. Brooklyn Investment Group lifted its stake in Organon & Co. by 1,012.3% during the 1st quarter. Brooklyn Investment Group now owns 3,070 shares of the company's stock valued at $46,000 after acquiring an additional 2,794 shares in the last quarter. BI Asset Management Fondsmaeglerselskab A S bought a new position in Organon & Co. during the 1st quarter valued at $51,000. Mirae Asset Global Investments Co. Ltd. bought a new position in Organon & Co. during the 1st quarter valued at $60,000. Finally, PARK CIRCLE Co lifted its stake in Organon & Co. by 640.7% during the 1st quarter. PARK CIRCLE Co now owns 4,000 shares of the company's stock valued at $60,000 after acquiring an additional 3,460 shares in the last quarter. 77.43% of the stock is currently owned by institutional investors.

Organon & Co. Stock Performance

Shares of NYSE OGN traded up $0.13 during mid-day trading on Monday, reaching $10.58. 3,518,312 shares of the company's stock were exchanged, compared to its average volume of 3,794,799. The firm has a market capitalization of $2.75 billion, a price-to-earnings ratio of 3.93, a price-to-earnings-growth ratio of 0.95 and a beta of 0.60. Organon & Co. has a 52 week low of $8.01 and a 52 week high of $19.83. The company has a debt-to-equity ratio of 11.98, a current ratio of 1.65 and a quick ratio of 1.13. The firm has a 50-day moving average price of $9.71 and a two-hundred day moving average price of $10.64.

Organon & Co. (NYSE:OGN - Get Free Report) last released its earnings results on Tuesday, August 5th. The company reported $1.00 EPS for the quarter, topping analysts' consensus estimates of $0.94 by $0.06. The company had revenue of $1.59 billion for the quarter, compared to analysts' expectations of $1.55 billion. Organon & Co. had a return on equity of 163.88% and a net margin of 11.15%.The business's revenue for the quarter was down .8% compared to the same quarter last year. During the same period in the previous year, the business posted $1.12 EPS. Organon & Co. has set its FY 2025 guidance at EPS. Analysts predict that Organon & Co. will post 3.68 EPS for the current year.

Organon & Co. Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, September 11th. Stockholders of record on Friday, August 15th were paid a dividend of $0.02 per share. This represents a $0.08 dividend on an annualized basis and a dividend yield of 0.8%. The ex-dividend date was Friday, August 15th. Organon & Co.'s payout ratio is presently 2.97%.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.